Varian Medical Systems Inc

Varian Medical Systems — Q1 2018 Earnings Presentation

36 slides from Varian Medical Systems's earnings presentation, Jan 24, 2018

  1. Slide 1: First Quarter Fiscal Year 2018

    J. Michael Bruff Vice President, Investor Relations mike.bruff@varian.com January 24, 2018 First Quarter Fiscal Year 2018

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1

  3. Slide 3: Long-Term Strategy

    Long - Term Strategy

  4. Slide 4: Global leader in radiation therapy

    Eclipse ™ Treatment planning system RapidPlan ™ Knowledge - based planning software Calypso ® Real - time tracking technology Edge ™ System Full - body radiosurgery platform Halycon ™ Image - guided IMRT treatment platform TrueBeam ® /VitalBeam ™ Trilogy ® /Clinac ® /UNIQUE ™ Treatment procedures wi

  5. Slide 5: Long-term growth and value creation strategy

    Long - term growth and value creation strategy 5 Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology

  6. Slide 6: Expand addressable market to patient-centered care coordination

    Long - term growth and value creation strategy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions 6 Interventional oncology Surgical oncology Diagnostic imaging Radiation oncology Precision medicine Medical oncology Generate insights Call on all oncologists Aggregate data Dissem

  7. Slide 7: Growth priorities and strategic enablers

    Growth priorities and strategic enablers 7 We are here Global Leader in Radiation Therapy Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Long - Term Growth and Value Creation Strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Marke

  8. Slide 8: Growth priority: Strengthen our leadership in radiation therapy

    Growth priority: Strengthen our leadership in radiation therapy (1) Based on company estimates and industry reports and data Executing on HyperArc launch our high - definition radiotherapy technology ⁃ 19 orders in the first quarter ⁃ 60% are upgrades Global market leader in radiation therapy, incre

  9. Slide 9: Growth priority: Extend global footprint

    Growth priority: Extend global footprint 55% international orders mix in Oncology; 12% international orders growth ⁃ EMEA orders growth of 19% ⁃ APAC orders growth of 6% ⁃ Latin American orders growth of - 3% 40% of Halcyon orders in emerging markets, since May launch ⁃ ~90% of emerging market order

  10. Slide 10: Growth priority: Expand addressable market

    Growth priority: Expand addressable market Financial flexibility to evaluate investment opportunities including both organic and inorganic options ⁃ Cash flow from operations grew 118% ⁃ Decreased debt across the year Unique software customers grew 4% during the first quarter; newer applications fue

  11. Slide 11: 1Q FY 2018 Business Highlights

    1Q FY 2018 Business Highlights

  12. Slide 12: Year in review

    First patient treated with Varian HyperArc high - definition radiotherapy Varian publishes 2017 Sustainability Report Year in review 12 JANUARY 2017 FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DECEMBER 2017 Varian honored as one of the top 100 most sustainable companies Spin - off of Varex Varian names

  13. Slide 13: Financial highlights

    Cash Flow from Operations 1 ($M) $0 $50 $100 $150 $200 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Non - GAAP EPS ($) $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Financial highlights Operating Trends* Strong performance in key financial measures • Revenues up 13% due to h

  14. Slide 14: Varian linac install base

    Varian linac install base Install Base Trends Varian strengthened its global leadership in radiation therapy • Each geography grew respective install base in the first quarter 14 Q1FY17 Q3FY17 Q2FY17 Q4FY17 Q1FY18 7,630 Total 7,876 +3%

  15. Slide 15: Key wins

    Key wins Americas EMEIA APAC Spain – Osakidetza 2 TrueBeams Denmark tender 15 linacs – Mix of TrueBeams and Halcyon over 4 years Poland Ministry of Health national tender 5 linac s – 1 Halcyon, 1 TrueBeam , 3 VitalBeams India Agartala and Jaipur cancer centers 5 linacs – 2 TrueBeams , 3 Unique Alaba

  16. Slide 16: 1Q FY 2018 Financial Overview

    1Q FY 2018 Financial Overview

  17. Slide 17: Varian consolidated (GAAP) Key P&L Financial Metrics

    Varian consolidated (GAAP) Key P&L Financial Metrics 17 VARIAN FISCAL 2018 $M 1Q Y/Y Gross Orders $666 15% Revenues $679 13% Product $366 18% Services $313 7% Gross Margin $303 13% % of Revenues 44.6% 24 bps SG&A $125 - 37% % of Revenues 18.5% - 1471 bps R&D $56 12% % of Revenues 8.2% - 5 bps Operat

  18. Slide 18: Varian consolidated (non-GAAP) Key P&L Financial Metrics

    VARIAN FISCAL 2018 $M 1Q Y/Y Gross Orders $666 15% Revenues $679 13% Product $366 18% Services $313 7% Gross Margin $304 13% % of Revenues 44.8% 22 bps SG&A $122 - 18% % of Revenues 18.0% - 689 bps R&D $56 12% % of Revenues 8.2% - 5 bps Operating Earnings $126 84% 1 % of Revenues 18.6% 716 bps EPS (

  19. Slide 19: Tax Cuts and Jobs Act impact on first quarter results

    $0.0 $50.0 $100.0 $150.0 $200.0 $250.0 GAAP Tax on Earnings Impact of Mandatory Repatriaton of Unremitted Foreign Earnings Impact of Re- Measurment on Deferred Tax Assets Non-GAAP Tax on Earnings Tax Cuts and Jobs Act enactment Impact on First Quarter Fiscal Year 2018 Results The ‘Tax Cuts and Jobs

  20. Slide 20: Key Balance Sheet and Cash Flow Metrics

    Varian consolidated Key Balance Sheet and Cash Flow Metrics • Cash Flow from Operations more than doubled driven by operating income growth and working capital improvements Oncology DSO down from 108 to 103 days • Continuing to strengthen financial flexibility through operational execution and by st

  21. Slide 21: Oncology operating segment Key Financial Metrics

    Oncology operating segment Key Financial Metrics • Strong start to the year with orders growth at nearly 7%, with growth in all regions Oncology orders mix: North America 45%, International 55% 12 new orders for Halcyon in the quarter; 19 new orders for HyperArc • Product revenue growth of 20% drive

  22. Slide 22: Oncology gross orders by geography

    Oncology gross orders by geography AMERICAS 2% 1Q Y/Y APAC 6% 1Q Y/Y EMEA 19% 1Q Y/Y 22

  23. Slide 23: Particle Therapy operating segment Key Financial Metrics

    Particle Therapy operating segment Key Financial Metrics • 2 new orders of ProBeam ® Compact systems, both in the Americas region University of Alabama University of Miami • 4 th quarter in a row with 2 Proton orders • 7 operational sites with 24 rooms in 5 countries; 16 more sites in progress acros

  24. Slide 24: ProBeam proton therapy system sites

    ProBeam proton therapy system sites 23 ProBeam Sites Rooms Operational Centers Centers Under Development 70 24

  25. Slide 25: FY 2018 Guidance

    FY 2018 Guidance

  26. Slide 26: Updated Fiscal Year 2018 Guidance

    Varian consolidated Updated Fiscal Year 2018 Guidance Raising full fiscal year 2018 guidance after considering the following: • Stronger radiation therapy market performance; stronger performance of Varian in the market • Implementation of the Tax Cuts and Jobs Act 26 VARIAN $M FY16 Actual FY17 Actu

  27. Slide 27: 1Q FY 2018 Financial Overview

    1Q FY 2018 Financial Overview

  28. Slide 28: Non-GAAP disclosure

    Non - GAAP disclosure 28 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

  29. Slide 29: GAAP to non-GAAP reconciliation

    GAAP to non - GAAP reconciliation 29 (1) Includes $1.3 million, $1.2 million, $1.2 million, $1.3 million and $1.2 million, respectively in cost of revenues for the pe rio ds presented. (2) Other includes acquisition - related expenses and benefits. (3) Represents the tax effect of a change in law re

  30. Slide 30: Total revenues by sales classification

    Total revenues by sales classification 30 CC – Constant currency $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $309.2 $364.9 $326.2 $402.8 $365.6 Y/Y 18% Service revenues $292.3 $298.3 $306.6 $319.0 $312.9 Y/Y 7% Total revenues $601.5 $663.2 $632.8 $721.8 $678.5 Y/Y 13% Y/Y – CC 11% Pr

  31. Slide 31: Total revenues by region

    Total revenues by region 31 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas revenues $298.2 $341.6 $336.3 $368.6 $356.7 Y/Y 20% Y/Y – CC 20% EMEA revenues $184.0 $185.3 $169.5 $220.4 $193.0 Y/Y 5% Y/Y – CC - 2% APAC revenues $119.3 $136.3 $127.0 $132.8 $128.8 Y/Y 8% Y/Y – CC 10% Total revenues $

  32. Slide 32: Total Oncology revenues by sales classification

    Total Oncology revenues by sales classification 32 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $282.4 $334.8 $259.7 $353.7 $338.3 Y/Y 20% Y/Y – CC 18% Service revenues $288.8 $297.1 $304.7 $315.6 $311.1 Y/Y 8% Y/Y – CC 6% Total revenues $571.2 $631.9 $564.4 $669.3 $649.4 Y/Y 14% Y/Y

  33. Slide 33: Total Oncology revenues by region

    Total Oncology revenues by region 33 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas revenues $290.8 $332.0 $286.9 $347.1 $337.4 Y/Y 16% Y/Y – CC 16% EMEA revenues $169.0 $167.5 $157.6 $196.9 $183.5 Y/Y 9% Y/Y – CC 2% APAC revenues $111.4 $132.4 $119.9 $125.3 $128.5 Y/Y 15% Y/Y – CC 17% Total re

  34. Slide 34: Total Particle Therapy revenues by sales classification

    Total Particle Therapy revenues by sales classification 34 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Product revenues $26.8 $30.1 $66.5 $49.1 $27.3 Y/Y 2% Service revenues $3.5 $1.2 $1.9 $3.4 $1.8 Y/Y - 49% Total revenues $30.3 $31.3 $68.4 $52.5 $29.1 Y/Y - 4% VPT revenues as a percentage of total

  35. Slide 35: Oncology gross orders by region

    Oncology gross orders by region 35 $M 1Q FY17 2Q FY17 3Q FY17 4Q FY17 1Q FY18 Americas orders $293.6 $335.2 $331.9 $479.0 $299.5 Y/Y 2% Y/Y – CC 2% EMEA orders $160.1 $180.3 $204.5 $315.4 $190.4 Y/Y 19% Y/Y – CC 13% APAC orders $123.0 $119.5 $151.3 $153.0 $130.0 Y/Y 6% Y/Y – CC 6% Total orders $576.

  36. Slide 36: Our promise: People powering victories

    Our promise 36 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer

Varian Medical Systems — Q1 2018 Earnings Presentation on 6ix